181 related articles for article (PubMed ID: 34234879)
21. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
Hsieh MS; Lin MW; Lee YH
Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
[TBL] [Abstract][Full Text] [Related]
22. Comparative Characteristics of Napsin A, TTF 1 and EGFR Mutation Expression in Mucinous Lung Cell Carcinomas.
Genova SN; Belovezhdov VT; Bichev SN; Danev VH
Folia Med (Plovdiv); 2017 Jun; 59(2):174-182. PubMed ID: 28704186
[TBL] [Abstract][Full Text] [Related]
23. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
24. [Pulmonary adenocarcinoma with micropapillary pattern: a clinicopathologic and immunohistochemical study].
Zhang J; Liang ZY; Luo YF; Wan JW; Cao JL; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):651-6. PubMed ID: 20078967
[TBL] [Abstract][Full Text] [Related]
25. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
26. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
[TBL] [Abstract][Full Text] [Related]
27. Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.
Huo Z; Wu H; Li J; Li S; Wu S; Liu Y; Luo Y; Cao J; Zeng X; Liang Z
PLoS One; 2015; 10(11):e0143169. PubMed ID: 26575266
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
Xu Y; Zhu C; Qian W; Zheng M
J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
[TBL] [Abstract][Full Text] [Related]
29. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
30. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
31. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
32. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
Rekhtman N; Ang DC; Riely GJ; Ladanyi M; Moreira AL
Mod Pathol; 2013 Oct; 26(10):1307-19. PubMed ID: 23619604
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
Zhao J; Xiang C; Zhao R; Guo P; Zheng J; Han-Zhang H; Yu K; Zhang J; Han Y
BMC Cancer; 2020 Mar; 20(1):248. PubMed ID: 32209061
[TBL] [Abstract][Full Text] [Related]
34. Histopathological and molecular study for synchronous lung adenocarcinoma staging.
Donfrancesco E; Yvorel V; Casteillo F; Stachowicz ML; Patoir A; Tiffet O; Péoc'h M; Forest F
Virchows Arch; 2020 Jun; 476(6):835-842. PubMed ID: 31900636
[TBL] [Abstract][Full Text] [Related]
35. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
36. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
37. High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.
Talvitie EM; Vilhonen H; Kurki S; Karlsson A; Orte K; Almangush A; Mohamed H; Liljeroos L; Singh Y; Leivo I; Laitinen T; Kallajoki M; Taimen P
Neoplasia; 2020 Sep; 22(9):333-342. PubMed ID: 32585428
[TBL] [Abstract][Full Text] [Related]
38. IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
Rodriguez EF; De Marchi F; Lokhandwala PM; Belchis D; Xian R; Gocke CD; Eshleman JR; Illei P; Li MT
Cancer Med; 2020 Jun; 9(12):4386-4394. PubMed ID: 32333643
[TBL] [Abstract][Full Text] [Related]
39. What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?
Aherne EA; Plodkowski AJ; Montecalvo J; Hayan S; Zheng J; Capanu M; Adusumilli PS; Travis WD; Ginsberg MS
Lung Cancer; 2018 Apr; 118():83-89. PubMed ID: 29572008
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
